283 related articles for article (PubMed ID: 9233868)
1. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.
Gordin FM; Matts JP; Miller C; Brown LS; Hafner R; John SL; Klein M; Vaughn A; Besch CL; Perez G; Szabo S; El-Sadr W
N Engl J Med; 1997 Jul; 337(5):315-20. PubMed ID: 9233868
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
Moreno S; Miralles P; Diaz MD; Baraia J; Padilla B; Berenguer J; Alberdi JC
Arch Intern Med; 1997 Aug 11-25; 157(15):1729-34. PubMed ID: 9250234
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients.
Casado JL; Moreno S; Fortún J; Antela A; Quereda C; Navas E; Moreno A; Dronda F
Clin Infect Dis; 2002 Feb; 34(3):386-9. PubMed ID: 11753825
[TBL] [Abstract][Full Text] [Related]
4. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
[TBL] [Abstract][Full Text] [Related]
5. Isoniazid prophylaxis for high-risk patients with anergy and HIV infection.
Aguado JM; Pulido F; Moreno S
N Engl J Med; 1997 Dec; 337(23):1696-7; author reply 1697. PubMed ID: 9411240
[No Abstract] [Full Text] [Related]
6. Isoniazid prophylaxis for high-risk patients with anergy and HIV infection.
Dore GJ; Law MG; Kaldor JM
N Engl J Med; 1997 Dec; 337(23):1697. PubMed ID: 9411241
[No Abstract] [Full Text] [Related]
7. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
Scholten JN; Driver CR; Munsiff SS; Kaye K; Rubino MA; Gourevitch MN; Trim C; Amofa J; Seewald R; Highley E; Fujiwara PI
Clin Infect Dis; 2003 Dec; 37(12):1686-92. PubMed ID: 14689352
[TBL] [Abstract][Full Text] [Related]
8. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
9. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
[TBL] [Abstract][Full Text] [Related]
10. Active tuberculosis in individuals infected with human immunodeficiency virus after isoniazid prophylaxis.
Fitzgerald DW; Morse MM; Pape JW; Johnson WD
Clin Infect Dis; 2000 Dec; 31(6):1495-7. PubMed ID: 11096020
[TBL] [Abstract][Full Text] [Related]
11. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
[TBL] [Abstract][Full Text] [Related]
12. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
[TBL] [Abstract][Full Text] [Related]
13. Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Aug; 49(30):685-7. PubMed ID: 10947056
[TBL] [Abstract][Full Text] [Related]
14. Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals.
Saenghirunvattana S
J Med Assoc Thai; 1996 May; 79(5):285-7. PubMed ID: 8708519
[TBL] [Abstract][Full Text] [Related]
15. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.
Spector SA; Gelber RD; McGrath N; Wara D; Barzilai A; Abrams E; Bryson YJ; Dankner WM; Livingston RA; Connor EM
N Engl J Med; 1994 Nov; 331(18):1181-7. PubMed ID: 7935655
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
[TBL] [Abstract][Full Text] [Related]
17. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia.
Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn PP
J Trop Med Hyg; 1995 Feb; 98(1):9-21. PubMed ID: 7861484
[TBL] [Abstract][Full Text] [Related]
18. Questions about a placebo-controlled trial of preventive therapy for tuberculosis in HIV-infected Ugandans.
Turner MT
N Engl J Med; 1998 Mar; 338(12):841-2. PubMed ID: 9508640
[No Abstract] [Full Text] [Related]
19. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City.
Mannheimer SB; Sepkowitz KA; Stoeckle M; Friedman CR; Hafner A; Riley LW
Int J Tuberc Lung Dis; 1997 Aug; 1(4):319-25. PubMed ID: 9432387
[TBL] [Abstract][Full Text] [Related]
20. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Whalen CC; Johnson JL; Okwera A; Hom DL; Huebner R; Mugyenyi P; Mugerwa RD; Ellner JJ
N Engl J Med; 1997 Sep; 337(12):801-8. PubMed ID: 9295239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
